Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Curis, Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07271667CT.gov A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies | — | Recruiting | — | — | — |
NCT06634589CT.gov A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | — | Recruiting | — | — | — |
NCT05389423CT.gov Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas | — | Recruiting | — | — | — |
NCT03932331CT.gov Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies | — | Active Not Recruiting | — | — | — |
NCT03198650CT.gov A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies | — | Active Not Recruiting | — | — | — |
NCT02569476CT.gov BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Prednisone (this asset) | Curis, Inc. | P2 | BB · 65 |
| Cyclophosphamide | University Hospital, Basel, Switzerland | P2 | BB |
| Zanubrutinib | Curis, Inc. | P2 | BB |
| Adriamycin | Curis, Inc. | P2 | BB |
| Rituximab | Curis, Inc. | P2 | BB |
| Lenalidomide | M.D. Anderson Cancer Center | P2 | B |
| Obinutuzumab | BeOne Medicines | P1/2 | B |
| Acalabrutinib | AstraZeneca | P1/2 | B |
| 18f-fspg | Andrei Iagaru | P2 | B |
+42 more in the B-Cell Neoplasm cohort
Other indications for Prednisone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 74 |
| Diffuse Large B-Cell Lymphoma | — | P4 | BBB · 74 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Prednisone in B-Cell Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/prednisone-b-cell-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →